Repurposing Amlodipine for Glioblastoma: A Proteomics study with relevance to pharmacy practice
Main Article Content
Keywords
Glioblastoma , Amlodipine, Proteomics, Mitochondrial Dysfunction, Drug Repurposing
Abstract
Background: Glioblastoma (GBM) is a highly aggressive brain malignancy with limited treatment options due to recurrence, therapy resistance, and invasiveness. Chemotherapy, though essential, is often hindered by severe side effects and chemoresistance. This highlights the need for alternative therapies with reduced cytotoxicity. Recent studies suggest that calcium channel blockers, such as amlodipine, may exhibit anticancer properties across various malignancies. Objectives: This study aimed to investigate the molecular changes induced by amlodipine in U87 and U373 GBM cell lines using quantitative proteomics to assess its potential as a repurposed therapeutic agent. Methods: Quantitative proteomic analysis was performed using UHPLCESI- QTOF-MS on U87 and U373 GBM cell lines treated with amlodipine. Statistical analysis was conducted using a Student’s t-test with a q-value < 0.05 to identify significantly dysregulated proteins. Results: A total of 1,820 proteins in U87 and 2,250 proteins in U373 were identified. Statistical analysis revealed 77 significantly dysregulated proteins in U87 and 14 in U373. Functional enrichment analysis demonstrated distinct pathway alterations between the two cell lines following amlodipine treatment. In U87 cells, mitochondrial oxidative phosphorylation pathways were deactivated, including NADH dehydrogenase and mitochondrial respiratory chain complex, with significant downregulation of NDUFS1, NDUFS2, and MT-ND4, proteins essential for energy production. In U373 cells, the fluid shear stress and atherosclerosis pathways were activated, with SQSTM1/p62 significantly upregulated. Notably, SQSTM1 was upregulated in both cell lines (4.7-fold in U87 and 2.9-fold in U373), suggesting a potential link between calcium influx inhibition and GBM stress response mechanisms. Conclusion: This study provides a comprehensive molecular map of amlodipine-induced proteomic alterations in GBM, highlighting its potential as a repurposed therapeutic agent. The distinct pathway alterations observed between U87 and U373 cell lines underscore the complexity of GBM biology and suggest that calcium channel blockers may exert cell-line-specific effects.
References
2. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pacific Journal of Cancer Prevention. 2017;18(1):3-9.
3. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neuro-Oncology. 2014;16(suppl_4):iv1-iv63.
4. Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacological Reviews. 2018;70(3):412-45.
5. Rapp M, Baernreuther J, Turowski B, Steiger H-J, Sabel M, Kamp MA. Recurrence Pattern Analysis of Primary Glioblastoma. World Neurosurgery. 2017;103:733-40.
6. Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. Journal of Controlled Release. 2016;227:23-37.
7. Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Letters. 2015;367(1):69-75.
8. Soeda A, Hara A, Kunisada T, Yoshimura S-i, Iwama T, Park DM. The Evidence of Glioblastoma Heterogeneity. Scientific Reports. 2015;5(1):7979.
9. Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. Cancer. 2015;121(7):997-1007.
10. Haque A, Banik NL, Ray SK. Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci. 2011;98:187-234.
11. Esemen Y, Awan M, Parwez R, Baig A, Rahman S, Masala I, et al. Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review. International Journal of Molecular Sciences. 2022;23(5):2607.
12. Aly A, Singh P, Korytowsky B, Ling Y-L, Kale HP, Dastani HB, et al. Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. Neuro-Oncology Practice. 2019;7(2):164-75.
13. Ohgaki H, Kleihues P. Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. Journal of Neuropathology & Experimental Neurology. 2005;64(6):479-89.
14. Basso J, Miranda A, Sousa J, Pais A, Vitorino C. Repurposing drugs for glioblastoma: From bench to bedside. Cancer Letters. 2018;428:173-83.
15. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13(9):687-9.
16. Alqudah MA, Yaseen MM, Alzoubi KH, Al-Husein BA, Bardaweel SK, Abuhelwa AY, et al. Metabolomic Analysis, Antiproliferative, Anti-Migratory, and Anti-Invasive Potential of Amlodipine in Lung Cancer Cells. 2025:1215-29.
17. Alqudah MAY, Al-Samman R, Azaizeh M, Alzoubi KH. Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells. Biomed Rep. 2022;16(6):50.
18. Mohammad A.Y. Alqudah, et al. The interactive effect of amlodipine and chemotherapeutic agents in lung cancer cells. Informatics in Medicine Unlocked. 2022.
19. Fu B, Dou X, Zou M, Lu H, Wang K, Liu Q, et al. Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer. Front Pharmacol. 2022;13:902305.
20. Hassanein MM, Hagyousif YA, Zenati RA, Al-Hroub HM, Khan FM, Abuhelwa AY, et al. Metabolomics insights into doxorubicin and 5-fluorouracil combination therapy in triple-negative breast cancer: a xenograft mouse model study. 2025;11:1517289.
21. Abufares HI, Zenati RA, Soares NC, El-Huneidi W, Dahabiyeh LA, Al-Hroub HM, et al. A non-targeted metabolomics comparative study on plasma of pfizer and sinopharm COVID-19 vaccinated individuals, assessed by (TIMS-QTOF) mass spectrometry. 2024;10(15).
22. Heo YJ, Hwa C, Lee G-H, Park J-M, An J-Y. Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. 2021;44(7):433-43.
23. Abufares HI, Oyoun Alsoud L, Alqudah MA, Shara M, Soares NC, Alzoubi KH, et al. COVID-19 vaccines, effectiveness, and immune responses. 2022;23(23):15415.
24. Al-Amrani S, Al-Jabri Z, Al-Zaabi A, Alshekaili J, Al-Khabori MJ. Proteomics: Concepts and applications in human medicine. 2021;12(5):57.
25. Motaln H, Koren A, Gruden K, Ramšak Ž, Schichor C, Lah TT. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget. 2015;6(38):40998-1017.
26. Zenati RA, Giddey AD, Al-Hroub HM, Hagyousif YA, El-Huneidi W, Bustanji Y, et al. Evaluation of two simultaneous metabolomic and proteomic extraction protocols assessed by ultra-high-performance liquid chromatography tandem mass spectrometry. 2023;24(2):1354.
27. Liu Z, Yang LY, Hao JJ, Zhang N, Fan ZL, Cai HQ, et al. Nuclear-cytoplasmic translocation of SQSTM1/p62 protein enhances ESCC cell migration and invasion by stabilizing EPLIN expression. Exp Cell Res. 2024;435(1):113910.
28. Zhao Y, Zhu S. Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma. Biochem Genet. 2024;62(1):144-55.
29. Bandara AB, Drake JC, James CC, Smyth JW, Brown DA. Complex I protein NDUFS2 is vital for growth, ROS generation, membrane integrity, apoptosis, and mitochondrial energetics. Mitochondrion. 2021;58:160-8.
30. Ren L, Meng L, Gao J, Lu M, Guo C, Li Y, et al. PHB2 promotes colorectal cancer cell proliferation and tumorigenesis through NDUFS1-mediated oxidative phosphorylation. Cell Death & Disease. 2023;14(1):44.
31. Arezi P, Rezvani Z. The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer. Journal of Molecular Graphics and Modelling. 2018;85:242-9.
32. Xu J, Chen F, Zhu W, Zhang W. NPC1 promotes autophagy with tumor promotion and acts as a prognostic model for hepatocellular carcinoma. Gene. 2024;897:148050.
33. Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium–cancer signalling nexus. Nature Reviews Cancer. 2017;17(6):373-80.
34. Piste P, Sayaji D, Avinash M. Calcium and its Role in Human Body. Int J Res Pharm Biomed Sci. 2012;4:2229-3701.
35. Azab MA, Alomari A, Azzam AY. Featuring how calcium channels and calmodulin affect glioblastoma behavior. A review article. Cancer Treatment and Research Communications. 2020;25:100255.
36. Van Gisbergen M, Voets A, Starmans M, Coo F, Yadak R, Hoffmann R, et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutation Research/Reviews in Mutation Research. 2015;290.
37. Boyman L, Karbowski M, Lederer WJ. Regulation of Mitochondrial ATP Production: Ca(2+) Signaling and Quality Control. Trends Mol Med. 2020;26(1):21-39.
38. Matlin KS. The Heuristic of Form: Mitochondrial Morphology and the Explanation of Oxidative Phosphorylation. J Hist Biol. 2016;49(1):37-94.
39. Huang X-D, Chen Y-W, Tian L, Du L, Cheng X-C, Lu Y-X, et al. NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis. 2024;150(1):8.
40. Huang X-D, Chen Y-W, Tian L, Du L, Cheng X-C, Lu Y-X, et al. NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis. Journal of Cancer Research and Clinical Oncology. 2024;150(1):8.
41. Zickermann V, Wirth C, Nasiri H, Siegmund K, Schwalbe H, Hunte C, et al. Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. Science. 2015;347(6217):44-9.
42. Iverson TM, Singh PK, Cecchini G. An evolving view of complex II-noncanonical complexes, megacomplexes, respiration, signaling, and beyond. J Biol Chem. 2023;299(6):104761.
43. Xu Y, Xue D, Kyani A, Bankhead III A, Roy J, Ljungman M, et al. First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) antagonist for the treatment of pancreatic Cancer. 2023;6(8):1164-81.
44. Espina JA, Cordeiro MH, Milivojevic M, Pajić-Lijaković I, Barriga EH. Response of cells and tissues to shear stress. Journal of Cell Science. 2023;136(18).
45. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences. 2020;21(24):9739.
46. Qazi H, Shi Z-D, Tarbell JM. Fluid Shear Stress Regulates the Invasive Potential of Glioma Cells via Modulation of Migratory Activity and Matrix Metalloproteinase Expression. PLOS ONE. 2011;6(5):e20348.
47. Dibdiakova K, Majercikova Z, Galanda T, Richterova R, Kolarovszki B, Racay P, et al. Relationship between the Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Brain Tumors. International Journal of Molecular Sciences. 2024;25(5):2858.
48. Tang J, Li Y, Xia S, Li J, Yang Q, Ding K, et al. Sequestosome 1/p62: A multitasker in the regulation of malignant tumor aggression. 2021;59(4):77.
49. Tang J, Li Y, Xia S, Li J, Yang Q, Ding K, et al. Sequestosome 1/p62: A multitasker in the regulation of malignant tumor aggression (Review). Int J Oncol. 2021;59(4):77.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.